EVIA Life Sciences Inc., 2026-11-02
A new SEC Form D private-offering notice from Tokyo, a $5,498,154 filer-stated offering target in Biotech. The source filing is one click away.
What this filing says
Biotech company developing extracellular vesicle therapeutics using cell reprogramming technology, with a lead program targeting liver fibrosis and MASH.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- MitoAI Inc., 2026-11-04, $8.1M, Boston, MA
- Araceli Biosciences Inc., 2026-11-03, $4.5M, Tigard, OR
- Rgenta Therapeutics, Inc., 2026-11-03, $130.1M, Woburn, MA
- Palimpsest Bio Corp., 2026-10-30, $1M, Las Vegas, NV
- Synomis, Inc., 2026-10-30, $2.5M, Germantown, TN
- Tru Singular Health, Inc., 2026-10-30, $1M, Natick, MA
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.